AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20189089 — intervention group
Group type: COMPARATOR
Intervention: Audit feedback alone (n=7)
Number of subjects: 3311
Study 18536598 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg IVTA
Number of subjects: 45
Study 18536598 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg IVTA
Number of subjects: 45
Study 18536598 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg IVTA
Number of subjects: 45
Study 15815904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing of the tibia with traction
Number of subjects: 30
Study 15815904 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary nailing of the tibia without traction
Number of subjects: 30
Study 12448658 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: 25 microg/m2 bryostatin-1 given as a 24 hour continuous infusion weekly
Number of subjects: 34
Study 12448658 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: 120 microg/m2 bryostatin-1 given as a 72 hour continuous infusion every 2 weeks
Number of subjects: 34
Study 10503055 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting a box of unknown weight at 4.3 lifts/min
Number of subjects: 15
Study 7852514 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pamidronate, 150 mg/day for at least 5 years
Number of subjects: 20
Study 7852514 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 20
Study 7852514 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pamidronate
Number of subjects: 20
Study 1672494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 419
Study 1672494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 419
Study 1672494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 419
Study 1672494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study 7039328 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate
Number of subjects: 21
Study 7039328 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 21
Study 7039328 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate and Acetazolamide (combination)
Number of subjects: 21
Study 7039328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31877119 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week resistance training (RT) program (2 d·wk in the first 5 weeks; 3 d·wk in the last 5 weeks)
Number of subjects: 25
Study 31095946 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW muscle glycogen (1.5 g/kg carbohydrate, 3.0 g/kg fat)
Number of subjects: 12
Study 31095946 — intervention group
Group type: COMPARATOR
Intervention: AD muscle glycogen (6.0 g/kg carbohydrate, 1.0 g/kg fat)
Number of subjects: 12
Study 31095946 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW muscle glycogen
Number of subjects: 12
Study 31095946 — intervention group
Group type: COMPARATOR
Intervention: AD muscle glycogen
Number of subjects: 12
Study 31095946 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LOW and AD muscle glycogen
Number of subjects: 12
Study 28351168 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability exercises for 15 minutes/day in addition to conventional physiotherapy (5 days/week for 5 weeks)
Number of subjects: 79
Study 25829456 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMA (Texas Implementation of Medication Algorithm)
Number of subjects: 61
Study 25829456 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 61
Study 25124938 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-episiotomy protocol (experimental group)
Number of subjects: 0
Study 25124938 — intervention group
Group type: COMPARATOR
Intervention: Selective episiotomy (control group)
Number of subjects: 0
Study 22623749 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention for parents including printed resources and four 30-min telephone calls
Number of subjects: 394
Study 22623749 — intervention group
Group type: COMPARATOR
Intervention: Control group received generic printed nutrition information
Number of subjects: 394
Study 22623749 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention for parents
Number of subjects: 394
Study 20849715 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (0.25 g, twice daily)
Number of subjects: 60
Study 20849715 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 60
Study 17620777 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) + standard of care (RICE)
Number of subjects: 158
Study 17620777 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) + standard of care (RICE)
Number of subjects: 158
Study 15887025 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-km trial at the 10-km race speed (v2km)
Number of subjects: 10
Study 15887025 — intervention group
Group type: COMPARATOR
Intervention: 400-m trials at increasing speeds (v1, v2, v3)
Number of subjects: 10
Study 11251424 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with nitrous oxide (FI = 0.63 +/- 2.5)
Number of subjects: 45
Study 11251424 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane alone
Number of subjects: 45
Study 9855027 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 1650
Study 9855027 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 1650
Study 9855027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1650
Study 8110536 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar block alone
Number of subjects: 30
Study 8110536 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 30
Study 8110536 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia combined with retrobulbar block given after induction
Number of subjects: 30
Study 2848432 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT 4237 live attenuated bovine rotavirus vaccine
Number of subjects: 103
Study 2848432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 31097514 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 µg
Number of subjects: 1691
Study 31097514 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 µg
Number of subjects: 1691
Study 31097514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1691
Study 30650265 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinchuang Ointment (JO)
Number of subjects: 306
Study 30650265 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese herbal medicine ointment
Number of subjects: 306
Study 30650265 — intervention group
Group type: COMPARATOR
Intervention: MepilexAg
Number of subjects: 306
Study 25840297 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical neomycin sulfate/ polymyxin-B sulfate (3500 IU/mL neomycin sulfate/6000 IU/mL polymyxin-B sulfate) applied 1 hour before surgery (Group 1)
Number of subjects: 133
Study 25840297 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical neomycin sulfate/ polymyxin-B sulfate (3500 IU/mL neomycin sulfate/6000 IU/mL polymyxin-B sulfate) applied 1 day before surgery (Group 2)
Number of subjects: 133
Study 25840297 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine 1.0% irrigation
Number of subjects: 133
Study 23915067 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation programme with a smartphone app for 6 months
Number of subjects: 0
Study 23915067 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21830966 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA and DNase
Number of subjects: 210
Study 21830966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 21830966 — intervention group
Group type: EXPERIMENTAL
Intervention: DNase
Number of subjects: 210
Study 21830966 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 210
Study 19836707 — intervention group
Group type: COMPARATOR
Intervention: Formocresol
Number of subjects: 0
Study 19836707 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Number of subjects: 0
Study 19836707 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide/iodoform
Number of subjects: 0
Study 16901427 — intervention group
Group type: COMPARATOR
Intervention: Tibialis anterior contraction
Number of subjects: 0
Study 15023753 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node (SN) resection
Number of subjects: 0
Study 15023753 — intervention group
Group type: COMPARATOR
Intervention: Conventional axillary dissection
Number of subjects: 0
Study 10634336 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple drug (zidovudine, lamivudine, and indinavir)
Number of subjects: 58
Study 10634336 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine-lamivudine
Number of subjects: 58
Study 10634336 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine-indinavir
Number of subjects: 58
Study 10634336 — intervention group
Group type: COMPARATOR
Intervention: Control group (sustained viral suppression)
Number of subjects: 58
Study 10634336 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 58
Study 10634336 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 58
Study 10634336 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple drug cases
Number of subjects: 58
Study 10634336 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine-lamivudine arm
Number of subjects: 58
Study 9102023 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified K‐wire technique of Kapandjii
Number of subjects: 0
Study 9102023 — intervention group
Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 0
Study 1392755 — intervention group
Group type: EXPERIMENTAL
Intervention: Health visitor intervention including assessment and correction of nutritional deficiencies, medical conditions, environmental hazards, and fitness improvement; duration: 4 years.
Number of subjects: 674
Study 1392755 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health visitor intervention).
Number of subjects: 674
Study 29809091 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based health education model based on protection motivation theory (PMT)
Number of subjects: 231
Study 29809091 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 231
Study 31481074 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 160
Study 31481074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 28434662 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB)
Number of subjects: 40
Study 28434662 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (CBA)
Number of subjects: 40
Study 28434662 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB) for restenotic lesions
Number of subjects: 40
Study 28434662 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (CBA) for restenotic lesions
Number of subjects: 40
Study 25001888 — intervention group
Group type: EXPERIMENTAL
Intervention: CBOP/BEP (carboplatin, bleomycin, vincristine, cisplatin/BEP); 2×CBOP, 2×BO, and 3×BEP (bleomycin 15,000 IU)
Number of subjects: 89
Study 25001888 — intervention group
Group type: COMPARATOR
Intervention: BEP (bleomycin 30,000 IU); composed of four cycles over 12 weeks
Number of subjects: 89
Study 25001888 — intervention group
Group type: EXPERIMENTAL
Intervention: CBOP/BEP
Number of subjects: 89
Study 25001888 — intervention group
Group type: COMPARATOR
Intervention: BEP
Number of subjects: 89
Study 24854297 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of pressure ulcer (PU) grade ≥ II
Number of subjects: 563
Study 24854297 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall hospital mortality
Number of subjects: 563
Study 23116381 — intervention group
Group type: EXPERIMENTAL
Intervention: Work‐Ordered Day program participation
Number of subjects: 43
Study 23116381 — intervention group
Group type: COMPARATOR
Intervention: Control group (Program of Assertive Community Treatment team)
Number of subjects: 43
Study 19950739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19950739 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 microg/kg
Number of subjects: 100
Study 19950739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 50 microg/kg
Number of subjects: 100
Study 19950739 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 50 microg/kg plus Dexamethasone 0.5 mg/kg
Number of subjects: 100
Study 17307170 — intervention group
Group type: EXPERIMENTAL
Intervention: Asoprisnil 5 mg
Number of subjects: 129
Study 17307170 — intervention group
Group type: EXPERIMENTAL
Intervention: Asoprisnil 10 mg
Number of subjects: 129
Study 17307170 — intervention group
Group type: EXPERIMENTAL
Intervention: Asoprisnil 25 mg
Number of subjects: 129
Study 17307170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 15193944 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of an object with the right hand
Number of subjects: 0
Study 15193944 — intervention group
Group type: COMPARATOR
Intervention: Manipulation of an object with the left hand
Number of subjects: 0
Study 12681347 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention focused on pseudowords
Number of subjects: 13
Study 12681347 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention focused on vowel sounds
Number of subjects: 13
Study 12681347 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention focused on words
Number of subjects: 13
Study 12681347 — intervention group
Group type: COMPARATOR
Intervention: Passive listening
Number of subjects: 13
Study 10331682 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided amobarbital injection
Number of subjects: 0
Study 10331682 — intervention group
Group type: COMPARATOR
Intervention: Right-sided amobarbital injection
Number of subjects: 0
Study 10331682 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemisphere injection (second)
Number of subjects: 0
Study 10331682 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemisphere injection
Number of subjects: 0
Study 8768841 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogen (1.25 mg daily)
Number of subjects: 16
Study 8768841 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (100 micrograms/day)
Number of subjects: 16
Study 8768841 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH administration after oral estrogens
Number of subjects: 16
Study 8768841 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH administration after transdermal estrogens
Number of subjects: 16
Study 8768841 — intervention group
Group type: COMPARATOR
Intervention: GHRH-stimulated GH levels
Number of subjects: 16
Study 1847128 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (HFX) with total doses of 69.6 Gy
Number of subjects: 516
Study 1847128 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation (STD) with 60 Gy in 30 fractions in 6 weeks
Number of subjects: 516
Study 1847128 — intervention group
Group type: EXPERIMENTAL
Intervention: RTOG Stage III patients
Number of subjects: 516
Study 7039841 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dose of methyldopa
Number of subjects: 27
Study 7039841 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily dose of methyldopa
Number of subjects: 27
Study 3892270 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human insulin (BHI)
Number of subjects: 20
Study 3892270 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 20
Study 29671955 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian-delivered health behavior intervention
Number of subjects: 307
Study 27589542 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sildenafil and inhaled nitric oxide (iNO)
Number of subjects: 24
Study 27589542 — intervention group
Group type: COMPARATOR
Intervention: Placebo and inhaled nitric oxide (iNO)
Number of subjects: 24
Study 25355268 — intervention group
Group type: EXPERIMENTAL
Intervention: Community nursing intervention (health knowledge lecture and individual community nursing intervention)
Number of subjects: 120
Study 25355268 — intervention group
Group type: COMPARATOR
Intervention: Routine management (control group)
Number of subjects: 120
Study 22261815 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee icing for 30 minutes
Number of subjects: 20
Study 22261815 — intervention group
Group type: COMPARATOR
Intervention: Elbow icing for 30 minutes (Control)
Number of subjects: 20
Study 20056373 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast pumping 0.6h after drinking a 0.4g/kg dose of alcohol (pumped after group)
Number of subjects: 12
Study 20056373 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast pumping 1h before drinking a 0.4g/kg dose of alcohol (pumped before group)
Number of subjects: 12
Study 20056373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted condition
Number of subjects: 12
Study 20056373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed condition
Number of subjects: 12
Study 19216446 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (bolus 50 mg/kg and 0.5 g/h)
Number of subjects: 48
Study 19216446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16020773 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 20
Study 16020773 — intervention group
Group type: COMPARATOR
Intervention: No statins
Number of subjects: 20
Study 12848839 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR) project interventions
Number of subjects: 23
Study 12848839 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges faced by the partnership
Number of subjects: 23
Study 10855852 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy consisting of 6 cycles of CMF for patients with high TLI tumors
Number of subjects: 11
Study 10855852 — intervention group
Group type: COMPARATOR
Intervention: Local-regional therapy alone for patients with low TLI tumors
Number of subjects: 11
Study 8640621 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative tutorial
Number of subjects: 8
Study 1523878 — intervention group
Group type: EXPERIMENTAL
Intervention: Wy‐Ad7HZ6‐1
Number of subjects: 9
Study 1523878 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus type 7 vaccine
Number of subjects: 9
Study 1523878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6568095 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop method
Number of subjects: 45
Study 6568095 — intervention group
Group type: COMPARATOR
Intervention: Capped-syringe method
Number of subjects: 45
Study 6568095 — intervention group
Group type: COMPARATOR
Intervention: Double-bag method
Number of subjects: 45
Study 30871596 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual CRAFT
Number of subjects: 405
Study 30871596 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CRAFT
Number of subjects: 405
Study 30871596 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help CRAFT
Number of subjects: 405
Study 30871596 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 405
Study 29964043 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (25 mg/wk)
Number of subjects: 179
Study 29964043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 26723472 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation-based intervention (4 sessions over 2 weeks)
Number of subjects: 101
Study 26723472 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 101
Study 26723472 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation-based intervention
Number of subjects: 101
Study 24650819 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (target dose: .08 mg/kg)
Number of subjects: 152
Study 24650819 — intervention group
Group type: COMPARATOR
Intervention: No alcohol
Number of subjects: 152
Study 22770549 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone 300 mg
Number of subjects: 342
Study 22770549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg/kg
Number of subjects: 342
Study 22770549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study 20400766 — intervention group
Group type: EXPERIMENTAL
Intervention: Carto-Merge
Number of subjects: 299
Study 20400766 — intervention group
Group type: COMPARATOR
Intervention: Carto-XP
Number of subjects: 299
Study 18083472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatic psoas compartment (SPC) block
Number of subjects: 36
Study 18083472 — intervention group
Group type: COMPARATOR
Intervention: Sciatic femoral 3‐in‐1 (SF 3‐in‐1) block
Number of subjects: 36
Study 16236940 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-sparing thoracotomy (MT)
Number of subjects: 120
Study 16236940 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral thoracotomy (PT)
Number of subjects: 120
Study 12004273 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IL-12 (rhIL-12) dosed twice weekly for 4 weeks at < or = 100 ng/kg
Number of subjects: 0
Study 12004273 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 9585709 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (running)
Number of subjects: 46
Study 9585709 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (112.5 mg/day)
Number of subjects: 46
Study 9585709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 8593380 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU orally at 6-month intervals)
Number of subjects: 269
Study 8593380 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 269
Study 2582711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg every 8 hours
Number of subjects: 15
Study 2582711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg every 12 hours
Number of subjects: 15